Skip to main content

Table 3 Results of analysis of risk factors for PFS and OS

From: Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients

Factors PFS OS
  univariate multivariate Univariate multivariate
  HR(95%CI) P value HR(95%CI) P value HR(95%CI) P value HR(95%CI) P value
Age
(As a numerical variate)
1.013
(0.991–1.036)
0.247 1.008
(0.982–1.034)
0.559 1.011
(0.984–1.038)
0.429 0.998
(0.969–1.027)
0.871
Sex
Male 1.280
(0.630–2.598)
0.495 1.207
(0.560–2.599)
0.631 1.625
(0.678–3.897)
0.277 1.545
(0.594–4.016)
0.372
Female 1.00 1.00 1.00 1.00
Cytogenetics and Molecular Risk
Favorable 1.00 1.00 1.00 1.00
Intermediate 1.459
(0.501–4.252)
0.489 1.573
(0.469–5.280)
0.463 4.190
(0.555–31.654)
0.165 2.743
(0.294–25.590)
0.376
Adverse 1.538
(0.433–5.462)
0.506 1.809
(0.484–6.768)
0.379 4.011
(0.446–36.050)
0.215 6.744
(0.676–67.256)
0.104
Number of Induction Therapy Courses to achieve MRD-negative CR
1 1.00 1.00 1.00 1.00
More than 1 0.743
(0.359–1.539)
0.424 0.655
(0.286–1.498)
0.316 0.686
(0.284–1.660)
0.404 0.494
(0.188–1.295)
0.151
Consolidation Regimen
AML-87 0.798
(0.320–1.987)
0.627 1.019
(0.318–3.266)
0.975 1.274
(0.414–3.921)
0.673 1.858
(0.441–7.820)
0.398
AML-201 0.652
(0.252–1.687)
0.377 0.892
(0.320–2.488)
0.827 0.372
(0.093–1.493)
0.163 0.374
(0.088–1.592)
0.183
HDAra-C 1.00 1.00 1.00 1.00
DPLT
Hlgh 1.00 1.00 1.00 1.00
Low 3.106
(1.509–6.394)
0.002 2.894
(1.320–6.345)
0.008 2.525
(1.056–6.035)
0.037 3.077
(1.130–8.376)
.0.028